Search hospitals

>

California

>

Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Claim this profile

Auburn, California 95603

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Pancreatic Cancer

Conducts research for Ovarian Cancer

125 reported clinical trials

9 medical researchers

Photo of Sutter Cancer Centers Radiation Oncology Services-Auburn in AuburnPhoto of Sutter Cancer Centers Radiation Oncology Services-Auburn in AuburnPhoto of Sutter Cancer Centers Radiation Oncology Services-Auburn in Auburn

Summary

Sutter Cancer Centers Radiation Oncology Services-Auburn is a medical facility located in Auburn, California. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer, Ovarian Cancer and other specialties. Sutter Cancer Centers Radiation Oncology Services-Auburn is involved with conducting 125 clinical trials across 271 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.

Area of expertise

1

Breast Cancer

Global Leader

Sutter Cancer Centers Radiation Oncology Services-Auburn has run 32 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
HER2 positive
2

Lung Cancer

Global Leader

Sutter Cancer Centers Radiation Oncology Services-Auburn has run 27 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage IV

Top PIs

Clinical Trials running at Sutter Cancer Centers Radiation Oncology Services-Auburn

Pancreatic Cancer

Ovarian Cancer

Breast Cancer

Esophageal cancer

Lung Cancer

Kidney Cancer

Multiple Myeloma

Breast cancer

Cancer

Non-Small Cell Lung Cancer

Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Recruiting

4 awards

Phase 3

18 criteria

Image of trial facility.

Radiation Therapy

for Cancer with Bone Metastasis

This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual care for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual care may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Higher Dose Radiation Therapy

for Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.

Recruiting

2 awards

Phase 3

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Sutter Cancer Centers Radiation Oncology Services-Auburn?